GDF-9 Inhibitors

The chemicals listed above are not direct inhibitors of GDF-9 but may influence its activity or signaling pathways. GDF-9 is involved in ovarian follicular development and is a key factor in female fertility. The signaling of GDF-9 primarily occurs through the TGF-β pathway, involving serine/threonine kinase receptors like ALK4, ALK5, and ALK7. TGF-β receptor inhibitors such as SB-431542, A-83-01, LY364947, and Galunisertib (LY2157299) can indirectly affect GDF-9 signaling by inhibiting the receptors that mediate its activity. These inhibitors target the kinase activity of TGF-β type I receptors, which are crucial for the downstream signaling of GDF-9.

Compounds like RepSox, SD-208, and EW-7197 specifically target ALK5 and related receptors, which play a role in TGF-β signaling. By modulating these receptors, these inhibitors could indirectly influence GDF-9's biological effects. Anti-fibrotic drugs such as Pirfenidone and Tranilast, known to inhibit TGF-β, may also have indirect effects on GDF-9 signaling, given the shared pathways and receptors. LY2109761 and Vactosertib (TEW-7197) are dual inhibitors of TGF-β receptor I and II, potentially affecting multiple aspects of TGF-β signaling, including pathways involving GDF-9. Saracatinib (AZD0530), primarily a Src inhibitor, might have broader effects on kinase signaling, potentially influencing pathways relevant to GDF-9 activity.